BCL9 and prostate carcinoma: In relation to our findings, Ling, X. H. et al. have correlated the ectopic expression of miR-30c with repressed expression of Wnt pathway downstream targets, including CD44 and c-Myc in prostate cancer cells; they also observed upregulated expression of BCL9 in prostate tissues and identified that BCL9 was targeted by miR-30c [33].